Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company was founded in 1979 and is based in Ewing, New Jersey.
ATRS Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Antares Pharma Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Antares Pharma Inc ranked in the 0th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for ATRS, they are:
The company's compound free cash flow growth rate over the past 0.5 years comes in at -0.5%; that's greater than only 2.24% of US stocks we're applying DCF forecasting to.
As a business, Antares Pharma Inc experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Antares Pharma Inc? See AGHC, ALC, AMRN, MOR, and PACB.
Antares Pharma (ATRS) has entered into an exclusive license agreement with Ferring Pharmaceuticals for the marketed product NOCDURNA (desmopressin acetate), which is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate, in the U.S. Under the terms of...
Antares Pharma (NASDAQ: ATRS ) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia. Antares Pharma … Full story available on Benzinga.com
EWING, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced it will release its second quarter 2020 financial results and recent operating progress before the market opens on Thursday, August 6, 2020. Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 6, 2020 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-353-6461 or 1-334-323-0501 and entering access code 5888699. We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time. A replay of the conference call will be available from 11:30 a.m. ET on Thursday, August 6, 2020 through 11:30 a.m. ET on Saturday, Sep...